ArriVent plots next steps for lung cancer drug; Neuron23's $96.5M raise

Plus, news about Rivus, Amarin, Recordati, Liquidia, Healthcare Royalty, Lexeo, Perceptive, venBio, Novo Nordisk and Cidara: ArriVent to start another Phase 3 of lung cancer drug: In a Phase 1b trial, the Pennsylvania biotech is ...